Research Analysts Issue Forecasts for INTS Q1 Earnings

Intensity Therapeutics Inc. (NASDAQ:INTS) – Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for shares of Intensity Therapeutics in a research note issued to investors on Tuesday, April 14th. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings per share of ($1.19) for the quarter. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($1.18) per share. Brookline Capital Markets also issued estimates for Intensity Therapeutics’ Q2 2026 earnings at ($1.06) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.46) EPS, FY2027 earnings at ($2.40) EPS, FY2028 earnings at ($5.58) EPS and FY2029 earnings at $7.32 EPS.

Other research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, December 22nd. Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Freedom Capital upgraded Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Intensity Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

Intensity Therapeutics Price Performance

NASDAQ:INTS opened at $5.32 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.92 and a current ratio of 5.92. The company has a 50-day moving average of $6.69 and a 200-day moving average of $8.84. Intensity Therapeutics has a 52 week low of $4.63 and a 52 week high of $48.56. The company has a market capitalization of $13.51 million, a price-to-earnings ratio of -0.34 and a beta of 3.65.

Intensity Therapeutics (NASDAQ:INTS) last issued its earnings results on Friday, March 27th. The company reported ($0.31) EPS for the quarter.

Hedge Funds Weigh In On Intensity Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INTS. Jane Street Group LLC acquired a new stake in shares of Intensity Therapeutics during the fourth quarter worth approximately $26,000. Corient Private Wealth LLC acquired a new stake in shares of Intensity Therapeutics in the fourth quarter valued at $41,000. Mesirow Financial Investment Management Inc. raised its holdings in shares of Intensity Therapeutics by 81.8% in the third quarter. Mesirow Financial Investment Management Inc. now owns 200,000 shares of the company’s stock valued at $49,000 after buying an additional 90,000 shares during the last quarter. State Street Corp grew its holdings in Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the last quarter. Finally, Legacy Advisors LLC acquired a new stake in Intensity Therapeutics in the 4th quarter valued at about $63,000. 3.74% of the stock is currently owned by institutional investors and hedge funds.

Intensity Therapeutics News Summary

Here are the key news stories impacting Intensity Therapeutics this week:

• Positive Sentiment: Zacks upgraded INTS to a Zacks Rank #2 (Buy), signaling growing optimism around the company’s earnings prospects and helping lift investor sentiment. Zacks Upgrade
• Positive Sentiment: Brookline Capital Markets materially raised several multi‑year forecasts (notably FY2026 and FY2027 improved and FY2029 raised to $7.32 EPS), which investors may interpret as increased long‑term upside if the company executes. These upgrades contrast with near‑term losses and appear to be driving speculative interest. Brookline Estimates
• Positive Sentiment: Intensity received a Pinnacle Award for Excellence in Healthcare Innovation (Platinum, Innovator in Biotech Solutions) for its intratumoral platform and lead candidate INT230‑6 — a credibility boost that may support investor confidence in the science and partner/licensing potential. Pinnacle Award
• Neutral Sentiment: Brookline also published detailed quarter‑by‑quarter estimates showing continued near‑term losses (Q1–Q4 2026 forecasts are negative and FY2026 is projected as a loss), providing a clear roadmap of expected short‑term cash burn and dilution risk for investors. Quarterly Estimates
• Negative Sentiment: Despite some raised targets, Brookline cut its FY2028 EPS outlook (worsened to ($5.58)), and consensus estimates for the nearer term remain negative (current full‑year consensus ≈ ($1.18) EPS). The company is still loss‑making, small‑cap and volatile, so upside from upgrades is balanced by execution and clinical/regulatory risk. Estimate Revisions

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.